课题基金 / 基金详情

Microenvironmental Analysis of Drug Binding Sites on Human Serum Albumin and alpha_1-Acid Glycoprotein

Microenvironmental Analysis of Drug Binding Sites on Human Serum Albumin and alpha_1-Acid Glycoprotein
人血清白蛋白和α_1-酸性糖蛋白药物结合位点的微环境分析
批准号:
02807196
负责人:
OTAGIRI Masaki
金额:
$1.02万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (C)
财政年份:
1990
资助国家:
日本
项目状态:
已结题
起止时间:
1990 至 1991

项目摘要

项目成果

OTAGIRI Masaki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The present study was undertaken in a view to clarify the characteristics of the drug binding sites on human serum albumin(HSA)and alpha_1-acid glycoprotein(AGP)using different fluorescent probes whose binding are site specific to HSA and AGP. Results obtained are as follows.(1)Hydrophobic forces were the driving forces for the binding of drugs to both HSA and AGP as evidenced from the obtained correlation of binding affinities with partition coefficients, the thermodynamic analysis and the spectral analysis. Further, sialic acid was found to impart some role in the binding of drugs to AGP.(2)From the displacement data using the fluorescent probes it seems that there are three drug binding sites on HSA andone widened flexible drug binding site on AGP, respectively. Although the presence of three different binding sites on HSA is evidenced, it is rather reasonable to consider that these sites are not completely separated but significantly overlapped and influenced by each other.(3)The hydrophobicity of the drug binding sites on HSA were in the order of site II>site I>siteIII. For AGP, one drug binding area was evidenced, however, the hydrophobicity of the acidic drug binding site was found to be greater than that of basic drug binding site. Moreover, the binding sizes of the sites on HSA or AGP were found to be different. In addition, the microviscosity analysis, a newly developed method, also suggested that the flexibility of the site I was the smallest among all the drug binding sites on HSA and the acidic drug binding site was more flexible as compared with the basic drug binding site.
期刊论文(28)
专著(0)
科研奖励(0)
会议论文
M.Otagiri: "Effects of Tricyclic Drug on Induced Circular Dichrois Spectra of Dicumarol Bound to α_1ーAcid Glycoprotein" Biochem.Pharmacol.41. (1991)
M.Otagiri:“三环药物对与 α_1-酸性糖蛋白结合的双香豆素诱导圆二色光谱的影响”Biochem.Pharmacol.41。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Teruko Imai: "Pharmaceutical Evaluation of Ibuprofen Fast-absorbed Syrup Containing Low-Molecular Weight Gelatin" Journal of Pharmaceutical Sciences. 81. 141-144 (1992)
Teruko Imai:“含低分子量明胶的布洛芬快速吸收糖浆的药学评价”《药物科学杂志》。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masaki Otagiri: "Binding Characteristics of Coumarin Anticoagulants to Human alpha_1-Acid Glycoprotein and Human Serum Albumin" International Journal of Pharmaceutics. 59. 137-143 (1990)
Masaki Otagiri:“香豆素抗凝剂与人 α_1-酸性糖蛋白和人血清白蛋白的结合特征”国际药剂学杂志。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masaki Otagiri: "Investigation of the Interaction Mode of Phenothiazine Neuroleptics with α_1-Acid Glycoprotein" Journal of Pharmacy & Pharmacology. 44. 28-33 (1992)
Masaki Otagiri:“吩噻嗪安定药与 α_1-酸性糖蛋白相互作用模式的研究”《药学与药理学杂志》44. 28-33 (1992)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
26
    Development of novel hybrid anti-oxidant based on albumin fusion technology and its therapeutic application on acute radiation syndrome
    • 批准号:
      15K15008
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2015
    • 负责人:
      OTAGIRI Masaki
    • 依托单位:
    Construction of an Innovative Bone Marrow Delivery System of Anticancer Drug for Control of Malignant Tumors' Bone Metastasis
    • 批准号:
      25670085
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2013
    • 负责人:
      OTAGIRI Masaki
    • 依托单位:
    Design and Evaluation of Next Generation Albumin-thioredoxin Fusion Protein for Multiple Organ Failure Treatment
    • 批准号:
      24390043
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.06万
    • 财政年份:
      2012
    • 负责人:
      OTAGIRI Masaki
    • 依托单位:
    Development of effective blood purification treatment method usingHSA bound toxic comnpodus designed bpyhase display tecnohlogy
    • 批准号:
      23659088
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2011
    • 负责人:
      OTAGIRI Masaki
    • 依托单位:
    海外基金